Literature DB >> 10757332

Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma.

R Lai1, L J Medeiros, L Dabbagh, K S Formenti, R W Coupland.   

Abstract

Anaplastic large cell lymphoma (ALCL) has been recognized recently as a distinct clinicopathologic entity, restricted to a subset of CD30-positive diffuse large cell lymphomas of T/null lineage. Some of the characteristic features of ALCL, such as CD30 antigen expression and the presence of large pleomorphic lymphoid cells infiltrating lymph node sinuses, can be found rarely in diffuse large B-cell lymphomas. We collected 11 such cases, and their clinical, morphologic, and immunophenotypic features are reviewed. The age of the patients ranged from 36 to 82 years (mean, 63.2 years) with a male to female ratio of 1:1.2. All neoplasms were nodal with a sinusoidal infiltrative pattern, although four neoplasms also had foci of confluent growth. Eight tumors were composed predominantly of large pleomorphic cells with occasional Reed-Sternberg-like cells. The other three tumors had a higher proportion of large monomorphic lymphoid cells. Necrosis and admixed granulocytes were other common features. Immunophenotypically, all cases were positive for CD30 and CD20 or CD79a. All eight cases examined for anaplastic lymphoma kinase-1 immunoreactivity were negative. In situ hybridization for Epstein-Barr virus RNA was performed in eight cases; two were positive. Excluding one consultation case with no available clinical follow-up data, six patients died of the disease within 3 years and one had disease relapse within 1 year. We conclude that an unusual variant of diffuse large B-cell lymphoma can closely mimic ALCL. However, these neoplasms can be distinguished from ALCL by virtue of their B-lineage and lack of anaplastic lymphoma kinase-1 expression. Evidence of Epstein-Barr virus infection can be found in a small subset of these neoplasms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757332     DOI: 10.1038/modpathol.3880041

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  Anaplastic Diffuse Large B Cell Lymphoma: A Single Center Experience.

Authors:  Neha Singh; Ridhi Sood; Narendra Agrawal; Sunil Pasricha; Anurag Mehta
Journal:  Indian J Hematol Blood Transfus       Date:  2019-02-09       Impact factor: 0.900

2.  CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement.

Authors:  Hiroki Asano; Yoichi Imai; Satoshi Ota; Go Yamamoto; Tsuyoshi Takahashi; Masashi Fukayama; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-09-14       Impact factor: 2.490

3.  Large B-cell lymphoma with an unusual infiltrating pattern: report of two cases.

Authors:  Neil G Haycocks; X Frank Zhao
Journal:  Int J Clin Exp Pathol       Date:  2010-10-11

4.  Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.

Authors:  Leticia Quintanilla-Martinez; Daphne de Jong; Antoine de Mascarel; Eric D Hsi; Philip Kluin; Yaso Natkunam; Marie Parrens; Stefano Pileri; German Ott
Journal:  J Hematop       Date:  2009-12-22       Impact factor: 0.196

5.  Primary gastric Hodgkin's lymphoma expressing a B-Cell profile including Oct-2 and Bob-1 proteins.

Authors:  Makoto Saito; Shinya Tanaka; Akio Mori; Nobuyasu Toyoshima; Tatsuro Irie; Masanobu Morioka
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

Review 6.  Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.

Authors:  Ayako Sakakibara; Kei Kohno; Eri Ishikawa; Yuka Suzuki; Yuta Tsuyuki; Satoko Shimada; Kazuyuki Shimada; Akira Satou; Taishi Takahara; Akiko Ohashi; Emiko Takahashi; Seiichi Kato; Shigeo Nakamura; Naoko Asano
Journal:  J Clin Exp Hematop       Date:  2021-09-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.